Tomas Söderblom
Impact in
- Endocrinology top 2%
- Escherichia coli research studies
- Vibrio bacteria research studies
- Microbiology top 2%
- Bacterial Infections and Vaccines
Papers in
-
- Escherichia coli research studies 3
-
- Clostridium difficile and Clostridium perfringens research 3
- Antimicrobial Resistance in Staphylococcus 2
- Co-authors
- Agneta Richter‐Dahlfors (6 shared papers)Bernt Eric Uhlin (2 shared papers)Sun Nyunt Wai (2 shared papers)Marie Westermark (1 shared paper)Jan Oscarsson (1 shared paper)Barbro Lindmark (1 shared paper)Yoshimitsu Mizunoe (1 shared paper)Akemi Takade (1 shared paper)
In The Last Decade
Tomas Söderblom
11 papers receiving 831 citations
Peers
Comparison fields: 5 of 75
- Endocrinology 245
- Microbiology 257
- Molecular Medicine 119
- Applied Microbiology and Biotechnology 14
- Infectious Diseases 118
Countries citing papers authored by Tomas Söderblom
This map shows the geographic impact of Tomas Söderblom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomas Söderblom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomas Söderblom more than expected).
Fields of papers citing papers by Tomas Söderblom
This network shows the impact of papers produced by Tomas Söderblom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomas Söderblom. The network helps show where Tomas Söderblom may publish in the future.
Co-authors
The 25 scholars most cited alongside Tomas Söderblom, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2003 | 426 | |
| 2 | 2000 | 196 | |
| 3 | 2013 | 66 | |
| 4 | 2005 | 57 | |
| 5 | 2010 | 34 | |
| 6 | 2006 | 19 | |
| 7 | 2003 | 14 | |
| 8 | 2014 | 12 | |
| 9 | 2001 | 11 | |
| 10 | 2003 | 8 | |
| 11 | 2007 | 2 |
About Tomas Söderblom
Tomas Söderblom is a scholar working on Endocrinology, Infectious Diseases, Molecular Biology, Epidemiology and Clinical Biochemistry, having authored 11 papers that have together received 845 indexed citations. Recurring topics across this work include Escherichia coli research studies (3 papers), Clostridium difficile and Clostridium perfringens research (3 papers), Pneumonia and Respiratory Infections (2 papers), Antimicrobial Resistance in Staphylococcus (2 papers), Bacterial Identification and Susceptibility Testing (2 papers), Antibiotic Resistance in Bacteria (2 papers), Antibiotic Use and Resistance (1 paper) and Streptococcal Infections and Treatments (1 paper). The work is most often cited by research in Endocrinology (245 citations), Microbiology (257 citations), Molecular Medicine (119 citations), Applied Microbiology and Biotechnology (14 citations) and Infectious Diseases (118 citations). Tomas Söderblom has collaborated with scholars based in Sweden, Czechia and Japan. Frequent co-authors include Agneta Richter‐Dahlfors, Bernt Eric Uhlin, Sun Nyunt Wai, Marie Westermark, Jan Oscarsson, Barbro Lindmark, Yoshimitsu Mizunoe, Akemi Takade, Jana Jaß and Anita Aperia. Their work appears in journals such as Clinical Microbiology and Infection, Pediatric Research, International Journal of Medical Microbiology, Cellular Microbiology and Nature.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.